A61K 38 - Medicinal preparations containing peptides

Patents for A61K 38 - Medicinal preparations containing peptides (316,240)
11/2001
11/15/2001	US20010041672 Luteinizing hormone releasing hormone analogs or a combination with antiestrogen which is selected from raloxifen, droloxifen, centchroman or derivatives, useful for treating endometrioses and myomas ( gynecological conditions)
11/15/2001	US20010041671 Ophthalmic formulations
11/15/2001	US20010041670 Activity of thrombospondin (TSP-1), an antiangiogenic protein, can be modulated by stimulating or inhibiting the activity of Histidine-Rich Glycoprotein (HRGP) or a protein that includes thrombospondin binding motif of HRGP
11/15/2001	US20010041669 Administering to mammal an effective amount of a hormonally inactive insulin or insulin analogue
11/15/2001	US20010041668 Selecting compound that is functionally equivalent to a gene product expressed in an embryo's extraembryonic tissue, causing the compound to access the cells to stimulate cells to undergo hematopoiesis and vascular growth
11/15/2001	US20010041356 Novel subunits of NADH dehydrogenase
11/15/2001	US20010041355 Regulation of human nerve growth factor-related G protein-coupled receptor
11/15/2001	US20010041353 Isolated nucleic acids
11/15/2001	US20010041337 Polypeptides
11/15/2001	US20010041193 Mixture of ascorbic acid, zinc salt and tyrosine compound
11/15/2001	US20010041190 Breathing mixture of drug and carrier powder
11/15/2001	US20010041181 Relieving pain related to muscle activity or contracture, antispasmodic
11/15/2001	US20010041177 Biomarker molecule CD163, antibody complex
11/15/2001	US20010041171 Polymer with pendant acid functional groups; will not degrade in the gastrointestinal tract
11/15/2001	DE10113324A1 A combined plant coagulate composition, process for the manufacture thereof and uses thereof
11/15/2001	DE10022092A1 Stabilisiertes Protein-Präparat und Verfahren zu seiner Herstellung The stabilized protein preparation and process for its preparation
11/15/2001	DE10019119A1 New leukotriene Bx receptor gene, LTBx, useful for diagnosis and treatment of LTBx-related diseases
11/15/2001	CA2804977A1 Compositions and methods for demonstrating secretory immune system regulation of steroid hormone responsive cancer cell growth
11/15/2001	CA2415688A1 Enzymatic treatment of whey proteins for the production of antihypertensive peptides, the resulting products and treatment of hypertension in mammals
11/15/2001	CA2411244A1 Therapeutic pore-forming peptides
11/15/2001	CA2409759A1 Method and composition for the treatment of angiogenesis
11/15/2001	CA2408935A1 Method of treating immune pathologies with low dose estrogen
11/15/2001	CA2408889A1 Immunosuppressive compositions
11/15/2001	CA2408732A1 Modified es cells and es cell-specific gene
11/15/2001	CA2408664A1 F-box containing protein
11/15/2001	CA2408632A1 Ph domain-interacting protein
11/15/2001	CA2408576A1 Rh116 polypeptides and its fragments and polynucleotides encoding said polypeptides and therapeutic uses
11/15/2001	CA2408571A1 Mammalian receptor proteins; related reagents and methods
11/15/2001	CA2408559A1 Polynucleotides encoding for polymorphic isoforms of the pthrp protein, the encoded proteins and their therapeutic applications thereof
11/15/2001	CA2408486A1 Tetrahydroisoquinoline analogs useful as growth hormone secretagogues
11/15/2001	CA2408352A1 Nontoxic vernix compositions and method of producing
11/15/2001	CA2408349A1 Method of regulating angiogenesis unsing ryk protein
11/15/2001	CA2408344A1 Compounds and methods for the diagnosis and treatment of ehrlichia infection
11/15/2001	CA2408319A1 Cxcr4 antagonist treatment of hematopoietic cells
11/15/2001	CA2408297A1 Cancer diagnosis and assays for screening anti-cancer agents
11/15/2001	CA2408255A1 Methods for stimulating nervous system regeneration and repair by regulating arginase 1 and polyamine synthesis
11/15/2001	CA2408253A1 Compositions, kits, and methods for identification, assessment, prevention, and therapy of psoriasis
11/15/2001	CA2408228A1 Method for promoting neovascularization
11/15/2001	CA2408213A1 Protein complexes and assays for screening anti-cancer agents
11/15/2001	CA2408196A1 Sphingosine kinase and uses thereof
11/15/2001	CA2408166A1 Presenilin enhancers
11/15/2001	CA2408124A1 Transgenically produced decorin
11/15/2001	CA2408051A1 Nucleotide sequences involved in increasing or decreasing mammalian ovulation rate
11/15/2001	CA2408002A1 Enzymatic assays for screening anti-cancer agents
11/15/2001	CA2407897A1 Molecular antigen arrays and vaccines
11/15/2001	CA2407865A1 Novel eosinophil cationic proteins used in the treatment of asthmatic and allergic disorders
11/15/2001	CA2407864A1 Lipid metabolism enzymes
11/15/2001	CA2407858A1 Use of inhibitors of placental growth factor for the treatment of pathological angiogenesis, pathological arteriogenesis, inflammation, tumour formation and/or vascular leakage
11/15/2001	CA2407850A1 Cytoskeleton-associated proteins
11/15/2001	CA2407698A1 Repair of nerve damage
11/15/2001	CA2406583A1 Pharmaceutical composition comprising a factor viia and a factor xiii
11/15/2001	CA2400214A1 Fusion receptor from tnf family
11/15/2001	CA2395314A1 Compounds and methods for modulating cerebral amyloid angiopathy
11/15/2001	CA2347560A1 Oxidizing composition and uses for dyeing, permanently bending or bleaching keratin fibers
11/14/2001	EP1154019A2 G-protein coupled receptor (HFGAN72X)
11/14/2001	EP1153928A1 2-methyl-3-butenyl-1-pyrophosphoric acid salts and agents for treating lymphocytes
11/14/2001	EP1153620A2 Solid compositions exhibiting selective binding to dissolved iron
11/14/2001	EP1153615A1 Pharmaceutical formulation for intravenous or intramuscular octreotide administration
11/14/2001	EP1153610A1 Matrix protein compositions for inflammatory and infectious conditions
11/14/2001	EP1153609A1 Amino acid-containing albumin preparations
11/14/2001	EP1153608A1 Stabilised protein preparation and process for the manufacture thereof
11/14/2001	EP1153607A2 Growth hormone for the treatment of joint inflammation
11/14/2001	EP1153302A1 Diagnostics and therapeutics for macular degeneration
11/14/2001	EP1153301A1 Diagnostics and therapeutics for arterial wall disruptive disorders
11/14/2001	EP1153133A2 Human diacylglycerol kinase beta (hdagk beta) proteins and nucleotide sequences encoding the same
11/14/2001	EP1153131A2 Peroral gene therapy of diabetes and obesity
11/14/2001	EP1153129A1 Method of treating restenosis by antisense targeting of c-myc
11/14/2001	EP1153125A1 Deglycosylated kringle 1-5 region fragments of plasminogen and methods of use
11/14/2001	EP1153121A2 Secreted proteins and polynucleotides encoding them
11/14/2001	EP1153038A1 Therapeutics and diagnostics based on a il-1b mutation
11/14/2001	EP1153037A1 Human uncoupling proteins and polynucleotides encoding the same
11/14/2001	EP1153036A1 Alpha-2-macroglobulin therapies and drug screening methods for alzheimer's disease
11/14/2001	EP1153035A2 Human lipid-associated proteins
11/14/2001	EP1153034A1 Growth hormone secretagogues
11/14/2001	EP1152773A1 Methods of inactivating pathogens using broad-spectrum pulsed light
11/14/2001	EP1152771A2 Adjuvant and cell maturation agent
11/14/2001	EP1152770A1 Small peptides and methods for treatment of asthma and inflammation
11/14/2001	EP1152769A1 Yeast cell wall peptides and antibodies thereto
11/14/2001	EP1152767A2 Method for producing anti-tumor th1 cells
11/14/2001	EP1152757A2 Connective tissue softening
11/14/2001	EP1152752A1 Methods for preventing graft rejection and ischemia-reperfusion injury
11/14/2001	EP1152749A2 Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicles
11/14/2001	EP1152734A1 Modified calycins
11/14/2001	EP1152731A1 A skin care composition that mediates cell to cell communication
11/14/2001	EP1152723A1 Enzymatic treatment and prevention of hypertrophic skin
11/14/2001	EP1066380B1 Soluble t cell receptor
11/14/2001	EP1061938B1 Oral compositions at low dosage of cytotoxic proteins
11/14/2001	EP1001745B1 Artificial tear formulation
11/14/2001	EP0980250B1 Plant extracts for the treatment of increased bone resorption
11/14/2001	EP0894002A4 Novel peptides which inhibit complement activation
11/14/2001	EP0847400B1 Polymorphs of the prodrug 6-n-(l-ala-l-ala)-trovafloxacin
11/14/2001	EP0845998B1 Immunotherapy medicaments containing antibodies which specifically detect the mhcii antigen of a patient to be treated
11/14/2001	EP0799052B1 New antithrombotic formulation, process for its manufacturing, and use thereof
11/14/2001	EP0777482B1 Combined preparation for the therapy of immune diseases
11/14/2001	EP0774972B1 The use of des-aspartate-angiotensin i as an anti-cardiac hypertrophic agent
11/14/2001	EP0771555B1 Agent for external application with nutrient and protective properties
11/14/2001	EP0715653B1 Humanised antibodies
11/14/2001	EP0713527B1 Fungicidal methods and compositions for killing yeast and sporular microorganisms
11/14/2001	EP0712307B1 Methods for b-cell population control
11/14/2001	EP0688360B1 Bone stimulating factor

1 ... 2164 2165 2166 2167 2168 2169 2170 2171 2172 2173 2174 2175 2176 2177 2178 2179 2180 2181 2182 2183 2184 ... 3163